Home » Case Studies » Value Access and Pricing » Early P&MA Forecasting Su…

Early P&MA Forecasting Support

CBPartners recently provided early P&MA forecasting support for a pipeline asset in development for several inflammatory conditions via secondary research.


To support the indication prioritization for PRODUCT X by understanding the current and future landscape across several inflammatory diseases and informing early pricing and market access (P&MA) forecasting for PRODUCT X.



Conduct secondary research into the clinical treatment algorithms and current pricing and market access (P&MA) landscape of 19 inflammatory diseases to understand the unmet need, level of competition, payer management, contracting and pricing benchmarks. Run a pipeline assessment to predict shifts within the landscape and evolution in P&MA benchmarks. Synthesize findings to deliver a comprehensive indication-by-indication achievable net pricing strategy for early P&MA forecasting inputs.


  • Detailed XLS outlining current pricing and access status of competitor therapies including level of contracting and payer mix
  • Pipeline analysis including likely price comparator, achievable net price and likely level of payer management

Illustrative Outputs


CBP provided key P&MA data to inform inputs for the early P&MA forecast of PRODUCT X, allowing our client to assess the optimal launch strategy across 19 inflammatory conditions.